Therefore, we induced MI at P10 and subjected the mice to a 3-day treatment with 5 mg/kg SB225002, a CXCR2 receptor antagonist, to block the CXCR2 signaling pathway in the S100a9+Ly6c+ IMo subpopulation (Figure 7A). This evidence concerns the gene CXCR2 and myocardial infarction.